Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ganciclovir,Foscarnet Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : University Hospital, Lille
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Ganciclovir,Foscarnet Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : University Hospital, Lille
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Hepatitis B Immunoglobulin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Hannover Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins
Details : Undisclosed
Product Name : Hepatect
Product Type : Antibody
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Human Hepatitis B Immunoglobulin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Hannover Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cytofulvin,Inapplicable
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : University Hospital, Bordeaux
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Cytotect
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 22, 2021
Lead Product(s) : Cytofulvin,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : University Hospital, Bordeaux
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Normal Immunoglobulin,Inapplicable
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Recipient : RWTH Aachen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 07, 2017
Lead Product(s) : Human Normal Immunoglobulin,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : RWTH Aachen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BT062,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Biotest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 12, 2012
Lead Product(s) : BT062,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Biotest
Deal Size : Inapplicable
Deal Type : Inapplicable